319 related articles for article (PubMed ID: 30666845)
1. The Risk of Malignancy in Korean Patients with Rheumatoid Arthritis.
Lee H
Yonsei Med J; 2019 Feb; 60(2):223-229. PubMed ID: 30666845
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid arthritis and the risk of malignancy.
Cibere J; Sibley J; Haga M
Arthritis Rheum; 1997 Sep; 40(9):1580-6. PubMed ID: 9324011
[TBL] [Abstract][Full Text] [Related]
3. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
4. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
Cho SK; Lee J; Han M; Bae SC; Sung YK
Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
[TBL] [Abstract][Full Text] [Related]
5. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.
Mercer LK; Davies R; Galloway JB; Low A; Lunt M; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2013 Jan; 52(1):91-8. PubMed ID: 23238979
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, incidence, and risk factors of malignancy in patients with rheumatoid arthritis: a nationwide cohort study from Korea.
Ko KM; Moon SJ
Korean J Intern Med; 2023 Jan; 38(1):113-124. PubMed ID: 34407599
[TBL] [Abstract][Full Text] [Related]
7. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis.
Simon TA; Thompson A; Gandhi KK; Hochberg MC; Suissa S
Arthritis Res Ther; 2015 Aug; 17(1):212. PubMed ID: 26271620
[TBL] [Abstract][Full Text] [Related]
8. Risk of malignancy among patients with rheumatic conditions.
Thomas E; Brewster DH; Black RJ; Macfarlane GJ
Int J Cancer; 2000 Nov; 88(3):497-502. PubMed ID: 11054684
[TBL] [Abstract][Full Text] [Related]
9. Incidence and patterns of malignancies in a multi-ethnic cohort of rheumatoid arthritis patients.
Lim XR; Xiang W; Tan JWL; Koh LW; Lian TY; Leong KP; Koh ET;
Int J Rheum Dis; 2019 Sep; 22(9):1679-1685. PubMed ID: 31297986
[TBL] [Abstract][Full Text] [Related]
10. Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study.
Cordtz R; Mellemkjær L; Glintborg B; Hetland ML; Madsen OR; Jensen Hansen IM; Dreyer L
Rheumatology (Oxford); 2016 Jun; 55(6):1017-22. PubMed ID: 26912584
[TBL] [Abstract][Full Text] [Related]
11. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.
Harigai M; Nanki T; Koike R; Tanaka M; Watanabe-Imai K; Komano Y; Sakai R; Yamazaki H; Koike T; Miyasaka N
Mod Rheumatol; 2016 Sep; 26(5):642-50. PubMed ID: 26873430
[TBL] [Abstract][Full Text] [Related]
12. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology.
Sankila R; Garwicz S; Olsen JH; Döllner H; Hertz H; Kreuger A; Langmark F; Lanning M; Möller T; Tulinius H
J Clin Oncol; 1996 May; 14(5):1442-6. PubMed ID: 8622057
[TBL] [Abstract][Full Text] [Related]
13. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate.
Buchbinder R; Barber M; Heuzenroeder L; Wluka AE; Giles G; Hall S; Harkness A; Lewis D; Littlejohn G; Miller MH; Ryan PF; Jolley D
Arthritis Rheum; 2008 Jun; 59(6):794-9. PubMed ID: 18512713
[TBL] [Abstract][Full Text] [Related]
14. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
[TBL] [Abstract][Full Text] [Related]
15. Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data.
Jung SM; Kwok SK; Ju JH; Park YB; Park SH
Korean J Intern Med; 2019 May; 34(3):669-677. PubMed ID: 29172405
[TBL] [Abstract][Full Text] [Related]
16. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of opportunistic infection in early rheumatoid arthritis.
Kim H; Cho SK; Lee J; Bae SC; Sung YK
Int J Rheum Dis; 2019 Jul; 22(7):1239-1246. PubMed ID: 31090187
[TBL] [Abstract][Full Text] [Related]
18. Cancer morbidity of professional emergency responders in Korea.
Ahn YS; Jeong KS; Kim KS
Am J Ind Med; 2012 Sep; 55(9):768-78. PubMed ID: 22628010
[TBL] [Abstract][Full Text] [Related]
19. The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study.
Lin YC; Chou HW; Tsai WC; Yen JH; Chang SJ; Lin YC
Clin Rheumatol; 2015 Jul; 34(7):1195-202. PubMed ID: 25990004
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis.
Smitten AL; Simon TA; Hochberg MC; Suissa S
Arthritis Res Ther; 2008; 10(2):R45. PubMed ID: 18433475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
